Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Naïve Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo Trial

<p>Article full text</p> <p>The full text of this article can be found at <u>https://link.springer.com/article/10.1007/s40121-016-0110-5</u></p><p><u><br></u></p><p></p> <p>Provide enhanced content for this article</p> <p>If you are an author of this publication and would like to provide additional enhanced content for your article then please contact <a href="http://www.medengine.com/Redeem/”mailto:[email protected]”"><b>[email protected]</b></a>.</p> <p>The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.</p> <p>Other enhanced features include, but are not limited to:</p> <ul> <li>Slide decks</li> <li>Videos and animations</li> <li>Audio abstracts</li> <li>Audio slides</li> </ul

Scoring system for predictive baseline characteristics.

<p>Scoring system for predictive baseline characteristics.</p

Patient selection for the validation cohort.

<p>Patient selection for the validation cohort.</p

Rate of response in treatment-naive cirrhotic and noncirrhotic Caucasian and patients with HCV genotype 3 by baseline score.

<p>Patients with missing scores omitted (noncirrhotic; n = 48, cirrhotic; n = 11). ^a Patients with missing information on cirrhosis status were given the same score as no cirrhosis.</p

Sustained virologic response and relapse rates in treatment-naive Caucasian patients with HCV genotype 3 by baseline prediction score.

<p>A) Development cohort; B) Validation cohort SVR = sustained virologic response 24 weeks post-treatment. ^a 73 patients did not have a score and were omitted; of these, 46 (63.0%) achieved SVR. ^b Patients with end-of-treatment response and sufficient follow-up.</p

Relationship between age and sustained virologic response (SVR).

<p>Short vertical lines indicate the number of patients with SVR (black lines) and no SVR (grey lines). Open circles represent probability of SVR according to the GAM analysis. Closed circles represent empirical probability for midpoints of deciles.</p

Relationship between bodyweight and sustained virologic response (SVR).

<p>Short vertical lines indicate the number of patients with SVR (black lines) and no SVR (grey lines). Open circles represent probability of SVR according to the GAM analysis. Closed circles represent empirical probability for midpoints of deciles.</p

Relationship between platelet count and sustained virologic response (SVR).

<p>Short vertical lines indicate the number of patients with SVR (black lines) and no SVR (grey lines). Open circles represent probability of SVR according to the GAM analysis. Closed circles represent empirical probability for midpoints of deciles.</p

Baseline demographic and disease characteristics.

<p>Baseline demographic and disease characteristics.</p

Relationship between alanine aminotransferase (ALT)/upper limit of normal (ULN) and sustained virologic response (SVR).

<p>Short vertical lines indicate the number of patients with SVR (black lines) and no SVR (grey lines). Open circles represent probability of SVR according to the GAM analysis. Closed circles represent empirical probability for midpoints of deciles. ALT/ULN = patients' ALT divided by the ULN for the local laboratory</p